高密度脂蛋白与脓毒症。
HDL and Sepsis.
机构信息
The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.
Department of Cardiology, Chinese PLA Central War Command General Hospital, Wuhan, China.
出版信息
Adv Exp Med Biol. 2022;1377:129-139. doi: 10.1007/978-981-19-1592-5_10.
Sepsis has been recognized as a global health burden in the year 2017 for its high morbidity and mortality. HDL, a cholesterol transporter, also plays vital role in inflammation besides its typical role in reverse cholesterol transportation. In septic patients, HDL levels dropped significantly. HDL exerts a variety of protective effects in the pathophysiology of sepsis including acting on pathogens, inhibiting macrophage inflammatory reaction, and modulating endothelial function in sepsis. Studies have shown that rHDL or apoA-I mimetic peptides could be therapeutic potentials in sepsis. HDL has caused increasing concern as a potential therapeutic agent.
2017 年，脓毒症因其高发病率和死亡率而被确认为全球健康负担。高密度脂蛋白（HDL）作为一种胆固醇转运蛋白，除了在胆固醇逆向转运中发挥典型作用外，在炎症中也起着至关重要的作用。在脓毒症患者中，HDL 水平显著下降。HDL 在脓毒症的病理生理学中发挥多种保护作用，包括作用于病原体、抑制巨噬细胞炎症反应以及调节脓毒症中的内皮功能。研究表明，rHDL 或载脂蛋白 A-I 模拟肽在脓毒症中可能具有治疗潜力。HDL 作为一种潜在的治疗药物引起了越来越多的关注。
Zotero 插件